Compare GGT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGT | ARMP |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.7M | 199.7M |
| IPO Year | 1995 | 1996 |
| Metric | GGT | ARMP |
|---|---|---|
| Price | $4.06 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 419.0K | 248.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.87 | $2.94 |
| 52 Week High | $4.37 | $14.98 |
| Indicator | GGT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 42.23 |
| Support Level | $4.00 | $3.98 |
| Resistance Level | $4.25 | $5.63 |
| Average True Range (ATR) | 0.04 | 0.52 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 92.38 | 16.01 |
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.